|Bid||105.920 x 800|
|Ask||105.990 x 900|
|Day's Range||105.830 - 106.770|
|52 Week Range||91.330 - 119.050|
|PE Ratio (TTM)||41.75|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||116.38|
The Wilmington, Massachusetts-based company said it had net income of $1.08 per share. Earnings, adjusted for amortization costs and non-recurring costs, were $1.38 per share. The results exceeded Wall ...
Charles River Laboratories International, Inc. today reported its results for the first quarter of 2018. For the quarter, revenue from continuing operations was $494.0 million, an increase of 10.8% from $445.8 million in the first quarter of 2017.
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an extension of its long-standing collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinson’s disease (PD). Since 2011, Charles River and MJFF have worked together to accelerate the discovery of therapies for PD. With MJFF support, Charles River has launched a new project, focused on in vivo phenotyping of an α-synuclein knockout model and an α-synuclein A53T knockin model.
Charles River Laboratories International, Inc. today announced the expansion of its service capabilities in early discovery screening. Charles River is the first contract research organization to offer clients access to Apricot Designs' Dual Arm system for high-throughput absorption, distribution, metabolism, and excretion to identify potential lead compounds in North America and Europe.
Charles River Laboratories International, Inc. will release first-quarter 2018 financial results on Thursday, May 10th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 10th, at 8:30 a.m.
Charles River Laboratories International, Inc. today announced that its team of oncology experts is presenting 13 scientific posters, both independently and collaboratively with clients, and will highlight an enhanced oncology portfolio at the American Association for Cancer Research Annual Meeting.
Charles River Laboratories International, Inc. and PathoQuest today announced an expansion of their strategic partnership agreement to provide next-generation sequencing services to the biologics industry.
Charles River Laboratories International, Inc. announced today that it has completed the previously announced acquisition of MPI Research for approximately $800 million in cash, subject to certain customary adjustments.
Charles River Laboratories International, Inc. announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 5.5% senior notes due 2026 in an unregistered offering.
Moody's Investors Service, ("Moody's) assigned a B1 rating to Charles River Laboratories International Inc.'s ("Charles River") proposed $500 million senior unsecured notes. At the same ...
Charles River Laboratories International, Inc. announced today that it has refinanced its existing $1.0 billion of revolving credit facility due 2021 with a new $1.55 billion revolving credit facility due 2023, and its existing $650.0 million of term loan facility due 2021 with a new $750.0 million term loan facility due 2023 .
Charles River Laboratories International, Inc. recently announced several key expansions to its global Biologics Testing Solutions infrastructure to support the characterization, development, and release of biologics and biosimilars.
Charles River Laboratories International, Inc. announced today that it will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Florida, on Tuesday, March 6th, at 3:25 p.m.
Examining how Charles River Laboratories International Inc (NYSE:CRL) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simpleRead More...
Charles River Laboratories International, Inc. recently announced the launch of its new online Tumor Model Compendium web interface. The new Compendium interface provides oncology researchers with an easily accessible, user-friendly resource to identify tumor models based on specific molecular and histological properties, accompanied by selected patient information.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Stock Monitor: Fluidigm Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 15, 2018 / Active-Investors.com has just released a free research report on Charles River Laboratories International, ...
Moody's Investors Service ("Moody's") affirmed Charles Rivers Laboratories International Inc.'s ("Charles River") Ba2 Corporate Family Rating and Ba2-PD Probability of Default Rating, ...